A Look at Johnson & Johnson’s Stock Performance
Johnson & Johnson (JNJ) closed June 18 at $121.30 per share. The stock reached a 52-week low of $118.60 on May 29 as the company scrapped a Phase 1b/2 trial for its drug, Darzalex, for the treatment of advanced or metastatic non-small cell lung cancer patients, in combination with Roche’s (RHHBY) Tecentriq. Since then, the stock has risen ~1.6%.